Get the Stockscreener App
21.47
3.57%
0.74
After Hours:
21.77
0.30
+1.40%
Apellis Pharmaceuticals Inc stock is traded at $21.47, with a volume of 6.49M.
It is up +3.57% in the last 24 hours and down -5.13% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$20.73
Open:
$21
24h Volume:
6.49M
Relative Volume:
2.53
Market Cap:
$2.71B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-10.58
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-23.78%
1M Performance:
-5.13%
6M Performance:
+11.76%
1Y Performance:
-21.24%
1-Day Range:
$19.25
$21.80
1-Week Range:
$19.25
$30.48
52-Week Range:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
21.47 | 2.62B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Regression analysis insights on Apellis Pharmaceuticals Inc. performanceQuarterly Profit Review & Daily Growth Stock Investment Tips - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Risk Factors & Expert Approved Momentum Ideas - newser.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockFed Meeting & Reliable Price Breakout Signals - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic value2025 Price Targets & High Return Stock Watch Alerts - newser.com
Will Apellis Pharmaceuticals Inc. (1JK) stock rise with strong economy2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
Apellis Pharmaceuticals Hits Day Low of $20.66 Amid Price Pressure - Markets Mojo
Brighton Jones LLC Buys Shares of 16,539 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc. recovery potential after sell off2025 Market WrapUp & Verified Momentum Stock Watchlist - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekWeekly Trend Recap & Smart Money Movement Tracker - newser.com
Why retail investors favor Apellis Pharmaceuticals Inc. stockJuly 2025 Closing Moves & Weekly Setup with ROI Potential - newser.com
Citigroup Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $45.00 at TD Cowen - MarketBeat
Is Apellis Pharmaceuticals Inc. stock attractive for income investorsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $45.00 by Analysts at HC Wainwright - MarketBeat
Robert W. Baird Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2025 Earnings Call Transcript - Insider Monkey
How sentiment analysis helps forecast Apellis Pharmaceuticals Inc.July 2025 Movers & Weekly High Return Opportunities - newser.com
Jennison Associates LLC Raises Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Y Intercept Hong Kong Ltd Has $2.84 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. stock maintain dividend yieldShort Setup & Smart Swing Trading Alerts - newser.com
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by AlphaQuest LLC - MarketBeat
How Apellis Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Real time scanner hits for Apellis Pharmaceuticals Inc. explainedPrice Action & Fast Gaining Stock Reports - newser.com
APLS: Citigroup Lowers Price Target Amidst Maintained Buy Rating - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastDividend Cut Warnings & Free Wealth Planning Blueprints - earlytimes.in
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates - sharewise.com
APLS Analyst Rating Update: TD Cowen Adjusts Price Target | APLS Stock News - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Beats Estimates By $0.64 EPS - MarketBeat
Apellis Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:APLS) 2025-10-31 - Seeking Alpha
Apellis Pharmaceuticals (APLS): Forecast 13% Annual Revenue Growth, Shares Trade at Deep Discount Heading Into Earnings - Yahoo Finance
APLS Stock: Baird Raises Price Target to $52, Maintains Outperfo - GuruFocus
APLS: HC Wainwright & Co. Lowers Price Target, Maintains 'Buy' Rating | APLS Stock News - GuruFocus
What valuation ratios show for Apellis Pharmaceuticals Inc. (1JK) stockTrade Risk Assessment & Low Volatility Stock Recommendations - newser.com
How moving averages guide Apellis Pharmaceuticals Inc. tradingMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings - TipRanks
Can Apellis Pharmaceuticals Inc. stock sustain market leadership2025 Pullback Review & Free Growth Oriented Trading Recommendations - newser.com
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Market Sentiment & Free Community Consensus Stock Picks - newser.com
Apellis Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Apellis down as Goldman Sachs cuts to sell on risks to outlook - MSN
Apellis Pharma earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Apellis’ $458M Shocker: FDA Win, Analyst Buzz & 20% Stock Whiplash - ts2.tech
Apellis (APLS) Shares Decline by Nearly 25% - GuruFocus
CapEx per share of Apellis Pharmaceuticals, Inc. – MUN:1JK - TradingView
Earnings call transcript: Apellis Pharmaceuticals Q3 2025 earnings beat expectations but stock tumbles - Investing.com Nigeria
Apellis (APLS) Shares Drop Sharply by Over 19% - GuruFocus
Apellis Gets A Rare Edge With Big Sobi Payout And Strong Drug Sales - Finimize
Apellis Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):